Received 10 January 2016; accepted 26 February 2016; published 29 February 2016
There is growing evidence that vitamin D deficiency can be a contributing factor in the development of both type 1 and type 2 diabetes  - . Vitamin D might function as an immune and insulin secretion modulator  and had also been shown to down regulate the production of several cytokines in in vitro studies  . Additionally, vitamin D might also provide protection against major health problems such as autoimmune disease, cardio-metabolic disease, and cancer   . It also remains unclear if vitamin D deficiency is associated with insulin resistance and if there is a role for vitamin D replacement in the treatment of glucose intolerance. Hormones such as the adipokines; adiponectin and resistin are a possible link between insulin resistance and adiposity. Furthermore, several clinical and epidemiological studies have revealed positive associations between plasma concentrations of resistin and pro-inflammatory cytokines in diabetics and coronary heart diseases  - . Another study done by Vilarrasa  in a healthy population showed no significant associations between plasma concentrations of 25 (OH) D and resistin whereas plasma 25 (OH) D showed a negative correlation with body mass index―body fat, waist, hip circumference and with leptin. National surveys in Kingdom of Saudi Arabia (KSA) reported an increasing prevalence of diabetes and obesity affecting more than a quarter of the adult population  - . Also in Kingdom of Saudi Arabia, more than 50% of the population suffer from hypovitaminosis D (<50 nmol/l)  . To further evaluate whether vitamin D deficiency is associated with diabetes mellitus and changes of adipokine secretion especially resistin, we measured serum 25 (OH) D concentrations and resistin level for Saudi diabetic patients and those at high risk to develop atherosclerotic cardiovascular diseases. Such assessment will predict the individuals at high risk to develop complications, taking into account a comprehensive list of risk factors, including age, obesity and hyperlipidemia.
2. Subjects and Methodology
This study is a cross-sectional, health facilities-based study, conducted in central state, Kingdom of Saudi Arabia during April 2012-September 2013. Patients are diagnosed as type-1 or type-2 Diabetes Mellitus according to the WHO classification (1999) and fulfilling the set criteria for enrollment as exclusion of pregnant women. One hundred and eleven diabetic patients; 52 males and 59 females, were enrolled in the study. Fifty six were recruited as age and sex matched healthy controls. Written consents were obtained and investigations were conducted according to the principles expressed in the Declaration of Helsinki. Blood; 5 ml, was collected from each participant in plain vacutainers and serum was separated after centrifugation and stored at −20˚C till analysis.
Demographic and clinical data of the study groups were collected through a questionnaire filled by patients prior to samples collection. Weight and height of participants were measured and BMI was calculated.
2.1. Laboratory Investigations
Glycated haemoglobin was measured from venous blood samples collected following overnight fast using the chromatographic based method  . Triglycerides and high-density lipoprotein cholesterol (HDL-C) were determined by enzymatic methods. 25-hydroxyvitamin D was measured by specific ELISAs in accordance with the instructions provided by the manufacturer (IDS, Tyne & Wear, UK). Serum resistin on fasting blood was measured using a human resistin Quantikine ELISA kit Cat DRSNOO (R & D Systems, UK) following the manufacturer’s protocol.
2.2. Statistical Analysis
Parametric (mean + standard deviation (SD) and nonparametric measurements were calculated using SPSS package version 18 windows. Correlation coefficient and T-test was used and P ≤ 0.05 was considered as significant.
One hundred and eleven diabetics and 56 healthy controls were recruited in this study. The mean age of the diabetic group was (33.29 ± 23.13) and the mean duration of diabetes mellitus was (8.61 ± 7.27) year and the body mass index (BMI) was (27.42 ± 10.1).
Table 1 shows the levels of vitamin 25 (OH) D and resistin in the study group. Serum resistin level in the diabetic group was higher than that of the control group (P < 0.001).
Table 2 shows the mean ± standard deviation (SD) of biochemical parameters in diabetic groups. BMI was higher in DM type-2 and lower in DM type-1 compared to the reference values; while glycated haemgolobin was higher than the reference values in the 2 groups. The liver enzymes are in the normal range for the study group. For lipid prolife, only triacyglycerol showed higher result than the reference value in the 2 diabetic groups. Biochemical parameters for kidney function test, creatine is normal while the plasma urea levels are to the upper reference values.
Table 1. The level of vitamin 25 (OH) D and resistin levels in the study group.
Table 2. Biochemical parameters in the Study groups (mean ± SD).
Table 3 shows vitamin D and resistin levels in diabetic complications. The highest level of resistin was for nephropathy, neuropathy and cardiopathy while the lowest was found in hyperlipidemia. There is significant difference in the resistin level between cardiopathy, nephropathy and retinopathy compared to the healthy control. The level of vitamin 25 (OH) D was also high in patients with hyperlipidemia and neuropathy and the lowest was found in nephropathy, this may explain the role of kidney function on vitamin D levels.
Table 4 shows the level of resistin level and vitamin 25 (OH) D accordingly to the gender, positive family history of diabetes mellitus, statin medication and vitamin 25 (OH) D supplementation. Vitamin 25 (OH) D levels showed genetic link (P = 0.006) with positive family history for the first degree relative whereas resistin showed non-significant genetic link (P = 0.07). In this study, no significant increase for resistin and vitamin D levels was found with vitamin D supplementation or taking statins; the cholesterol lowering drugs. There is weak correlation between resistin level and hypertension and strong correlation between incidence of hypertension and hyperlipidemia and the use of statin drugs P values ≤ 0.0001.
Table 5 shows the correlation of plasma vitamin 25 (OH) D and resistin with biochemical parameters. There is significant negative correlation between resistin level and vitamin 25 (OH) D in type 2 diabetes mellitus reflecting the roles of vitamin D in type-2 diabetes mellitus (P value 0.043). Vitamin 25 (OH) D level showed significant positive correlation with creatinine and urea (P-values 0.018, 0.036) respectively. Whereas resistin level showed profound, non-significant correlation (P = 0.078) with calcium level. All other biochemical parameters including lipid profile were not significantly correlated with plasma resistin or vitamin 25 (OH) D level.
This cross-sectional study which was intended to explore whether there is a relationship between 25’ (OH) vitamin D and serum resistin levels among diabetic patients that might affect the severity of the disease. The study showed that vitamin 25 (OH) D level was at the bottom of the normal range in the control and the diabetic groups. The life style of Saudi subjects such as no sun exposure and the high body fat mass which leads to limited bioavailability of vitamin D caused by the trapping of vitamin D in adipose tissue may further increase the
Table 3. Resistin and vitamin 25 (OH) D levels with diabetic complications.
Table 4. Resistin and vitamin 25 (OH) D levels accordingly to gender, family history of diabetes, statin medication and vitamin 25 (OH) D supplementation.
Table 5. The correlation between vitamin 25 (OH) D and resistin with biochemical parameters in diabetes mellitus type-2 (P-values).
*P value ≤ 0.05.
risk of vitamin D deficiency. Therefore it is possible that vitamin D deficiency may contribute to insulin resistance and the development of metabolic syndrome secondary to inflammation aggravated by the increased resistin levels in diabetics. Our results revealed that the level of serum resistin slightly increases among diabetic patients compared to the control group (P ≤ 0.061). Given the obesity-insulin resistance-inflammation link and convergence of adipocyte and macrophage function, resistin may provide unique insight into links between obesity, inflammation, and metabolic syndrome risk in humans. This connection between macrophage derived resistin and adipose tissues may further clarify the understanding of obesity as an inflammatory state and implicates resistin as a potential modulator of that state. Vitamin D has been shown to inhibit antigen-induced T cell proliferation and cytokine production  , acting as an immune-modulatory agent  . Recently, vitamin D has been proposed to also have anti-inflammatory properties. Interestingly, the serum resistin level among patient with type 2 diabetes was found to be higher than those of type 1 and non-diabetic control. Serum resistin level in this study showed to be much higher level in neuropathy and nephropathy compared to the other complications, whereas vitamin 25 (OH) D was slightly increased in hyperlipidemia and neuropathy. Hyperlipidemia showed lower resistin level compared to the other complications. This may reflect the effect of hypolipidemic drugs on circulating resistin in diabetic subjects and slight increase in vitamin 25 (OH) D. Blood urea and creatinine showed significant correlation with the resistin level and vitamin 25 (OH) D, while vitamin 25 (OH) D showed negative correlation with resistin in type-2 diabetes mellitus. The role of low vitamin 25 (OH) D and increased resistin as pro-inflammatory may affect the kidneys dysfunction. Thus circulating vitamin 25 (OH) D and resistin levels were associated with general inflammation, and renal disease. Our findings do not fully support the hypothesis that vitamin D deficiency is associated with poorer glycemic control which can be caused by β-cell dysfunction as well as insulin resistance as there was no correlation between HB A1c and vitamin D level (P = 0.874). On the other hand the effect of vitamin D on diabetes might be mediated through the increased serum resistin level at decreased levels of vitamin 25 (OH) D as seen in type-2 diabetes mellitus through negative correlation between resistin and vitamin D in the present study. This effect would be influenced by obesity while such correlation was not detected in type-1 diabetes mellitus or non-diabetic study group.
This study showed significant negative correlation between vitamin 25 (OH) D and resistin level in type-2 diabetes mellitus. The correlation of vitamin D and resistin with urea may reflect their involvement in kidney dysfunction and the circulating vitamin 25 (OH) D and resistin levels are associated with general inflammation in renal diseases. The level of serum resistin showed slight increase in diabetic patients compared to control group and it was higher in type-2 diabetes mellitus. More efforts are needed to explore the physiological mechanism of vitamin 25 (OH) D and resistin action in metabolic disorders.
To investigate the impact of vitamin D treatment in diabetic and the role of vitamin D on glucose homeostasis and resistin as an inflammatory marker, future studies should use highly sensitive measures of insulin sensitivity and β-cell serum markers as well as other inflammatory markers.
The cross-sectional nature of the study and the small sample size limits the findings of the study. Several major confounders were also not included including season which has a counterintuitive effect in the vitamin D status of citizens residing in the Gulf region  .
The project was reviewed and approved by the Institutional Review board-IRP King Fahad Medical City, Log number 11-040. All patients were consented before their enrollment in the study.
This study was funded by SRC, Faculty of Medicine, King Fahad Medical City under grant no.10/32/1.
 Bland, R., Markovic, D., Hills, C.E. and Hughes, S.V. (2004) Expression of 25-Hydroxyvitamin D3-1 Alpha-Hydroxylase in Pancreatic Islets. The Journal of Steroid Biochemistry and Molecular Biology, 121, 89-90. http://dx.doi.org/10.1016/s0960-0760(04)00149-9
 Parekh, D., Sarathi, V., Shivane, V.K., Bandgar, T.R., Menon, P.S. and Shah, N.S. (2010) Pilot Study to Evaluate the Effect of Short-Term Improvement in Vitamin D Status on Glucose Tolerance in Patients with Type 2 Diabetes. Endocrine Practice 16, 600-608. http://dx.doi.org/10.4158/EP09300.OR
 Von Hurst, P.R., Sonehouse, W. and Coad, J. (2010) Vitamin D Supplementation Reduces Insulin Resistance in South Asian Women Living in New Zealand Who Are Insulin Resistant and Vitamin D Deficient: A Randomized, Placebo-Controlled Trial. British Journal of Nutrition, 103, 549-555.
 Bourlon, P.M., Billaudel, B. and Faure-Dussert, A. (1999) Influence of Vitamin D3 Deficiency and 1,25-Dihydroxyvitamin D3 on Denovo Insulin Biosynthesis in the Islets of the Rat Endocrine Pancreas. Journal of Endocrinology, 160, 87-95. http://dx.doi.org/10.1677/joe.0.1600087
 Van Etten, E. and Mathieu, C. (2005) Immunoregulation by 1,25-Dihydroxyvitamin D3: Basic Concepts. The Journal of Steroid Biochemistry and Molecular Biology, 97, 93-101.
 Khoo, A.L., Chai, L.Y.A., Koenen, H.J.P.M., Sweep, F.C.G.J., Joosten, I., Netea, M.G. and van der Ven, A.J.A.M. (2011) Regulation of Cytokine Responses by Seasonality of Vitamin D Status in Healthy Individuals. Clinical & Experimental Immunology, 164, 72-79.
 de Boer, I.H., Kestenbaum, B., Shoben, A.B., Michos, E.D., Sarnak, M.J. and Siscovick, D.S. (2009) 25-Hydroxyvitamin D Levels Inversely Associate with Risk for Developing Coronary Artery Calcification. Journal of the American Society of Nephrology, 20, 1805-1812.
 Vilarrasa, N., Vendrell, J., Maravall, J., Elío, I., Solano, E., San José, P., García, I., Virgili, N., Soler, J. and Gómez, J.M. (2010) Is Plasma 25(OH) D Related to Adipokines, Inflammatory Cytokines and Insulin Resistance in Both a Healthy and Morbidly Obese Population? Endocrine, 38, 235-242.
 Osawa, H., Onuma, H., Ochi, M., et al. (2005) Resistin SNP-420 Determines Its Monocyte mRNA and Serum Levels Inducing Type 2 Diabetes. Biochemical and Biophysical Research Communications, 335, 596-602. http://dx.doi.org/10.1016/j.bbrc.2005.07.122
 Tsukahara, T., Nakashima, E., Watarai, A., et al. (2009) Polymorphism in Resistin Promoter Region at ?420 Determines the Serum Resistin Levels and May Be a Risk Marker of Stroke in Japanese Type 2 Diabetic Patients. Diabetes Research and Clinical Practice, 84, 179-186.
 Burnett, M.S., Devaney, J.M., Adenika, R.J., et al. (2006) Cross-Sectional Associations of Resistin, Coronary Heart Disease, and Insulin Resistance. The Journal of Clinical Endocrinology & Metabolism, 91, 64-68. http://dx.doi.org/10.1210/jc.2005-1653
 Patel, L., Buckels, A.C., Kinghorn, I.J., et al. (2003) Resistin Is Expressed in Human Macrophages and Directly Regulated by PPAR Gamma Activators. Biochemical and Biophysical Research Communications, 300, 472-476. http://dx.doi.org/10.1016/S0006-291X(02)02841-3
 Aljohani, N.J., Al-Daghri, N.M., Al-Attas, O.S., Alokail, M.S., Alkhrafy, K.M., Al-Othman, A., et al. (2013) Differences and Associations of Metabolic and Vitamin D Status among Patients with and without Sub-Clinical Hypothyroid Dysfunction. BMC Endocrine Disorders, 13, 31. http://dx.doi.org/10.1186/1472-6823-13-31
 Maquart, F.-X., Gillery, P., Bernard, J.-F., Mante, J.-P. and Borel, J.-P. (1980) A Method for Specifically Measuring Haemoglobin AIC with a Disposable Commercial Ion-Exchange Column. Clinica Chimica Acta, 108, 329-332. http://dx.doi.org/10.1016/0009-8981(80)90021-2
 Mathieu, C. and Adorini, L. (2002) The Coming of Age of 1,25-Dihydroxyvitamin D(3) Analogs as Immunomodulatory Agents. Trends in Molecular Medicine, 8, 174-179.
 Al-Daghri, N.M., Al-Attas, O.S., Alokail, M.S., Alkharfy, K.M., El-Kholie, E., Yousef, M., Al-Othman, A., Al-Saleh, Y., Sabico, S., Kumar, S. and Chrousos, G.P. (2012) Increased Vitamin D Supplementation Recommended during Summer Season in the Gulf Region: A Counterintuitive Seasonal Effect in Vitamin D Levels in Adult, Overweight and Obese Middle Eastern Residents. Clinical Endocrinology, 76, 346-350. http://dx.doi.org/10.1111/j.1365-2265.2011.04219.x